Česky

English

HERPES SIMPLEX

Virologie

Epidemiologie

Klinický obraz

VAKCÍNY

Výroba

Farmakologie

Klinické údaje

SPC

Literatura

OSTATNÍ

Specifický léčebný program

Literatura
Určeno jen pro odbornou lékařskou veřejnost
M.Petráš, aktualizace: 24.01.2008

1	Feyzi E, Trybala E, BergstrÖm T, Lindahl U, and Spillman D. Structural Requirement of Heperin Sulfate for Interaction with Herpes Simplex Virus Type 1 Virions and Isolated Glycoprotein C-*. JBC Online 1997;272(40):24850.
2	Nicola A V, Willis S H, Naidoo N N, Eisenberg R J, and Cohen G H. Structure-Function Analysis of Soluable Forms of Herpes Simplex Virus Glycoprotien D. J. Virol.1996(March);3815-3822.
3	Roller R J and Herold B C. Characterization of a BHK (TK-) Cell Clone Resistant to Postattachment Entry by Herpes Simplex Virus Types 1 and 2. J. Virol. 1997 (May);5805-5813.
4	Tal-Singer R, Peng C, Ponce De Leon M, Abrams W R, Banfield B W, Tufaro F, Cohen G H, and Eisenberg R J. Interaction of Herpes Simplex Virus Glycoprotein gC with Mammalian Cell Surface Molecules. J. Virol. 1995 (July); 4471-4483.
5	Bearer E L, Breakefield X O, Schuback D, Reese T S, and LaVail. Retrograde Axonal Transport of Herpes Simplex Virus: Evidence for a Single Mechanism and a Role for Tegument; Unpublished. Dept. of Pathology and Laboratory Medicine, Brown University.
6	Fields B N, Knipe D M, et al. Fundamental Virology-2nd Edition 1991; 7-93, 219-272, 841-899.
7	Walker J and Leib D A. Protection from Primary Infection and Establishment of Latency by Vaccination with Herpes Simplex Virus Type I Recombinant Deficient in the Viron Host Shutoff (vhs) Function. Vaccine 1998; 16[1], 1-5.
8	Perng G-C,Slanina S M, Yukht A, Drolet B S, Keleher Jr. W,Ghiasi H, Nesburn A B, and Wechsler S L. A Herpes Simplex Virus Type 1 Latency Associated Transcript Mutant with Increased Virulence and Reduced Spontanous Reactivation. J. Virol. 1999(Feb); 73 [2], 920-929
9	Perng G-C, Slainina S M, Yukht A, Drolet B S, Keleher Jr. W, Ghiasi H, Nesburn A B, and Wechsler S L. A Herpes Simplex Virus Type 1 Latency-Associated Transcript Mutant with Increased Virulence and Reduced Spontaneous Reactivation. J. Virol Online 1999 (Feb); 73 (2): 920-929.
10	Avitable E, Ward P L, Lazzaro C D, Torrisl M R, Roizman B, and Campadelli-Fiume G. The Herpes Simplex UL20 Protein Compensates for the Differential Disruption of Exocytosis of Virions and Viral Membrane Glycoproteins Associated with Fragmantation of the Golgi Apparatus. J. Virol. 1994 (July);7397-7405.
11	White D O and Fenner F J. Medical Virology: Fourth Edition. ACADEMIC PRESS 1994.19-38,91-272, 317-347.
12	Scopp,Irwin Walter. Oral Medicine: A Clinical Approach with Basic Science Correlation 1969; 87-89
13	Darby M L and Bushee E J. Mosby's: Comprehensive Review Of Dental Hygiene.Second Edition 1991; 207-208, 258, 268-269.
14	Bernstein D I and Stanbery L R. Herpes Simplex Virus Vaccines. Vaccine 1999; 17: 1681-1689.
15	Drawings of HSV Genital locations --http://www.herpes.org.nz/doihavegh.html\
16	Mikloska Z, Danis V A, Adams S, Lloyd A R, Adrian D L, and Cunningham A L. In Vivo Production of Cytokines and Beta (C-C) Chemokines In Human Recurrent Herpes Simplex Lesions- Do Herpes Simplex Virus - Infested Keratinocytes Contribute To Their Production? JID 1998;177(April) 827-838.
17	Stanberry L R. Control of STDs--the Role of Prophylactic Vaccines against Herpes Simplex Virus. Sex Transm. Inf. 1998;74, 391-394
18	Belshe R B. Textbook of Human Virology.PSG Publishing Company,Inc. 1994: 811-821.
19	Mikloska Z and Cunningham A L. Herpes Simplex Virus Type 1 Glycoproteins gB, gC and gD are Major Targets for CD4 T-Lymphocyte Cytotoxicity in HLR-DR expressing Human Epidermal Keratinocytes. J. Gen.Virol. 1998;79, 353-361.
20	Koelle D M, Corey L, Burke R L, Eisenberg R J, Cohen G H, Pichyangkura R, and Triezenberg S J. Antigenic Specificities from Recurrent Gential Herpes Simplex Virus Type 2 Lesions. J. Virol. 1994 (May); 2803-2810.
21	Koelle D M, Frank J M, Johnson M L and Kwok W W. Recogniton of Herpes Simplex Virus Type 2 Tegument Proteins by CD4 T Cells Infiltrating Human Genital Lesions. J. Virol. 1998 (Sept.); 72 [9]: 7476-7483.
22	Jerome K R, Tait J F, Koelle D M and Corey L. Herpes Simplex Virus Type 1 Renders Infected Cells Resistant to Cytotoxic T-Lymphocyte-Induced Apoptosis. J. Virol.1998 (Jan). 72 [1]: 436-441.
23	Kuby J. Immunology - 3rd Edition 1997; 374-375, 328, 336-352, 318-320.
24	Freidman H M, Wang L, Fishman N O, Lambris J D, Eisenberg R J, Cohen G, and Lubinski J. Immune Evasion Properties of Herpes Simplex Virus Type I Glycoprotein gC. J. Virol. 1996 (July); 4253-4260.
25	Nagashunmugam T, Lubinski J, Wang L, Goldstein L T, Weeks B S, Sundaresan P, Kang E H, Dubin G, and Friedman H M. In Vivo Immune Evasion Mediated by the Herpes Simplex Virus Type I Immunoglobulin G Fc Receptor. J. Virol. 1998 (July); 5351-5359.
26	Neumann L, Krass W, Uebel S, Jung G, and Tampe R. The Active Domain of The Herpes Simplex Virus Protien ICP47: A Potent Inhibitor of The Transporter Associated with Antigen Processing (TAP). J. Mol. Biol. 1997; 272, 484-492.
27	Galocha B, Hill A, Barnett B C, Dolan A, Raimondi A, Cook R F, Brunner J, µgeoch, and Ploegh L. The Active Site Of ICP47, a Herpes Simplex Virus - Encoded Inhibitor of the Major Histocompatibility Complex (MHC)-encoded Peptide Transporter Associated with Antigen Processing (TAP), Maps of the NH(2)-terminal 35 Residues. J. Exp. Med. 1997(May);185 [9], 1565-1572.
28	Burkhart CG. Perspectives concerning genital herpes. Infect Med 16(8): 525-528, 1999
29	Bednář M, Fraňková V, Schindler J, Souček A, Vávra A. Lékařská mikrobiologie. Marvil 1996
30	Daheshia M, Feldman LT, Rouse BT. Herpes simplex virus latency and the immune response. Current Opinoin in Microbiology 1: 430-435, 1998
31	Halioua B and Malkkin J E. Epidemiology of Gential Herpes -Recent Advances. Eur. J. Dermatol. 1999 (Apr-May);9 [3] 177-184.
32	Corey L and Handsfield H H. Gential Herpes and Public Health: Affressing a Global Problem. JAMA 2000 (Feb); 283 [6] 791-794.
33	Belshe R B. Textbook of Human Virology.PSG Publishing Company,Inc. 1994: 811-821.
34	Jean-Elie Malkin, Epidemiology of genital herpes simplex virus infection in Developed Countries, HERPES 11 Supplement 1, 2004, (2A-23A)
35	Aurelian L, Kokuba H and Smith C C. Vaccine Potential of a Herpes Simplex Virus Type 2 Mutant Deleted in the PK Domain of the Large Subunit of Ribonucleotide Reductase (ICP10). Vaccine1999;17: 1951-1963.
36	Corey L and Handsfield H H. Genital Herpes and Public Health: Addressing a Global Problem. JAMA 2000 (Feb 9);283 [6]:791-4.
37	Rinaldi G, Herpes simplex e patologie correlate, Monografie Bruschettini, Lupidon, 2004
38	Hirsh N.S. Principles and practice of infectious disease. G.L. Mandell et al., 2nd vol., Wiley Medical Publications. New York, 1979.
39	Hollinshead A.C., Docherty J.J. Comparative diagnosis of Viral diseases. E. Kunstak, C. Kunstak, Academic Press, New York, 1977.
40	Sheridan J.F., Aurelian L. Diagnos. Immunol. 1:245-246, 1983
41	Sture L. Surv. Immunol. Res. 4, suppl 1:24-29, 1985
42	Ashley R. et al. J. Med. Virol. 17:153-156, 1985
43	Aurelian L. in: Herpes and Papilloma Viruses. De Palo G, Rilke F. Zur Hausen H. 24-43. Serono Symposia Publications from Raven Press, New York, 1986
44	Zweerink H.J., Corey L. Infect. Immun. 31:624-639, 1981
45	Zweerink H.J., Corey L. Infect. Immun. 37:413-421, 1982
46	Stanberry L.R., Burke R.L., Myers M.G. J. Infect. Dis. 157(1): 156-163, 1988
47	Hakama M., Louhivouri K. in: Herpes and Papilloma Viruses, Vol. II. De Palo G., Rilke F. Zur Hausen H. Serono Symposia Publications from Raven Press, New York, Vol. 46, 1986
48	Giovarelli M. Viano I., Zucca M., Valbonesi R., Dianzani F. Infect. Immun. 16(3):849-852, 1977
49	Serafini Cessi F., Bellabarba C. Identificazione delle glicoproteine B eD (gB e gD) del virus Herpes simplex (HSV) nei prodotti Lupidon H e Lupidon G. Acta Toxicol, et Ther. 9(3):150, 1988
50	Ames B.N. et al. P.N.A.S. USA, 70 :782, 1973
51	Ames B.N. et al. P.N.A.S. USA, 70 :2281, 1973
52	Ames B.N. et al. Mutation research. 31 :347, 1975
53	Mc Cann J. et al. P.N.A.S. USA 73 :950, 1976
54	Maron D.M. et al. Mutation research. 113 :173, 1983
55	Magnusson B. et al. J. Invest. Dermatol. 32(3), 1969
56	Rapp F. University of Pennsylvania (USA). Reinbeker Kollokuium. Tel Aviv 1976
57	Petersen E.E. Oncogenizität von Herpes simplex Viren und Lupiodn. Haut Kr. 52(7):417-426, 1977
58	Bleidl D., et al. Herpes labialis and Herpes genitalis therapy by means of specific immune stimulation. Acta Toxicologica et Therapeutica, 8 (1):13-33,1987
59	Veneroni G., et al. Specific immunostimulation in the therapy of recurrent Herpes simplex 1 or 2. Bollettino Istituto Sieroterapico Milanese, 66(1):427-434,1987
60	Tiradritti L., et al. Clinical and immunological effect of an antiherpes vaccine in patients suffering from recurrent facial or genital Herpes: a preliminary study. Farmaci e Terapia, 5(3):195-205, 1988
61	Single dose toxicity, Toxicology II Institute, Pavia University (Italy), 1988, (nepublikovaná studie výrobce)
62	Single dose toxicity, Laboratorium für Pharmakologie und Toxicologie, Dir. Prof. F. Leuschner, Hamburg (Germany), 1980, (nepublikovaná studie výrobce)
63	Single dose toxicity, Toxicology II Institute, Pavia University (Italy); Laboratorium für Pharmakologie und Toxicologie, Dir. Prof. F. Leuschner, Hamburg (Germany), 1980, (nepublikovaná studie výrobce)
64	Single dose toxicity, Laboratorium für Pharmakologie und Toxicologie, Dir. Prof. F. Leuschner, Hamburg (Germany), 1980, (nepublikovaná studie výrobce)
65	Subacute toxicity (up to 3 months), Institute of Pharmacology - Dir. Prof. E. Loeschner, Hamburg (Germany), 1978, (nepublikovaná studie výrobce)
66	Subacute toxicity (up to 3 months), Institute of Toxicology II, University of Pavia (Italy), 1980, (nepublikovaná studie výrobce)
67	Chronic toxicity on rats (beyond 3 month), Institute of Toxicology II, University of Pavia (Italy), 1987-1988, (nepublikovaná studie výrobce)
68	Chronic toxicity on dogs (beyond 3 month), Institute of Toxicology II, University of Pavia (Italy), 1987-1988, (nepublikovaná studie výrobce)
69	Reproductive and development toxicity on rats, Institute of Toxicology II, University of Pavia (Italy), 1987-1988, (nepublikovaná studie výrobce)
70	Embryofoetal and perinatal toxicity on rats, Institute of Toxicology II, University of Pavia (Italy), 1988, (nepublikovaná studie výrobce)
71	Embryofoetal and perinatal toxicity on rabbits, Institute of Toxicology II, University of Pavia (Italy), 1988, (nepublikovaná studie výrobce)
72	Pre and post-natal toxicity on rats, Institute of Toxicology II, University of Pavia (Italy), 1988, (nepublikovaná studie výrobce)
73	Reverse mutation study on Salmonella typhimurium (ames test), Genetic and Microbiology Department, University of Pavia (Italy), 1988, (nepublikovaná studie výrobce)
74	Urinary assay, Host mediated assay, Institute of Toxicology II, University of Pavia (Italy), 1988, (nepublikovaná studie výrobce)
75	Subcutaneous micronucleus test in mice, Institute of Toxicology II, University of Pavia (Italy), 1988, (nepublikovaná studie výrobce)
76	DNA repair, Institute of Toxicology II, University of Pavia (Italy), 1988, (nepublikovaná studie výrobce)
77	Carcinogenic potential on rats, Institute of Toxicology II, University of Pavia (Italy), 1986-1988, (nepublikovaná studie výrobce)
78	Intracranial toxicity on mice, Laboratorium für Pharmakologie und Toxicologie, Dir. Prof. F. Leuschner, Hamburg (Germany), 1980, (nepublikovaná studie výrobce)
79	Passive anaphylaxis cutaneous reaction on rabbits, Laboratorium für Pharmakologie und Toxicologie, Dir. Prof. F. Leuschner, Hamburg (Germany), 1980, (nepublikovaná studie výrobce)
80	Anaphylactogenic stimulation of IgE on mice, Laboratorium für Pharmakologie und Toxicologie, Dir. Prof. F. Leuschner, Hamburg (Germany), 1980, (nepublikovaná studie výrobce)
81	Hypersensitivity maximization test, Laboratorium für Pharmakologie und Toxicologie, Dir. Prof. F. Leuschner, Hamburg (Germany), 1980, (nepublikovaná studie výrobce)
82	Qadripur S.A. Ergebnisse einer kontrollierten klinischen Studie mit dem Herpes
83	Weitgasser H. Kontrollierte Klinische Studie mit den Herpes
84	Koinis G. et al. Bericht uber eine Herpes
85	Eichman A. Therapie von Herpes Simplex Rezidivans. Z.Hautkr. 52(8):475
86	Schmersahl P. Et Al. Behandlungsergebnisse mit dem Herpes Simplex
87	Schneider J. et al. Zur Antigentherapie des Rezidivierenden Herpes Simplex mit dem Herpes Simplex
88	Mastrolorenzo A. et al. Multicentre clinical trial with herpes simplex virus vaccine in recurrent herpes infection. Int. J. Std & Aids. 6:431
89	Altomare G.F., et al. Recurrent Herpes simplex specific immuno-therapy with killed virus. Acta Toxicologica et Therapeutica, 7(3):201-210,1986
90	Bleidl D., et al. Herpes labialis and Herpes genitalis therapy by means of specific immune stimulation. Acta Toxicologica et Therapeutica, 8 (1):13-33,1987
91	Veneroni G., et al. Specific immunostimulation in the therapy of recurrent Herpes simplex 1 or 2. Bollettino Istituto Sieroterapico Milanese, 66(1):427-434,1987
92	Cristofolini M., et al. Controlled clinical trial of the immunological therapy of recurrent Herpes simplex infections. Rassegna di Dermatologia e Sifilografia, 40:13-22,1987
93	Tiradritti L., et al. Clinical and immunological effect of an antiherpes vaccine in patients suffering from recurrent facial or genital Herpes: a preliminary study. Farmaci e Terapia, 5(3):195-205, 1988
94	Lombardo N., et al. Clinical evaluation of anti-Herpes vaccine in relapsing Herps simplex infections. G. Ital. Dermatol. Venereol. 128:57-62, 1993
95	Catanzaro C., et al. Valutazione dell’efficacia del vaccino antierpetico nelle infezioni recidivanti da Herpes Simplex Virus. Chron. Derm. 1995, V, (3):347
96	Calista D, et al. Prophylactic treatment of recurrent herpes infections with specific immunostimulation with Lupidon G/H. Italian Journal of Dermatology and Venerology, 1997; 132 (1) 27-32.
97	Pivetti-Pezzi P, et al. Herpes Simplex Virus vaccine in recurrent herpetic ocular infection. Cornea, 1999, 18(1):47-51
98	Accorinti M, et al. Prevention of herpetic eye disease by specific immunotherapy with heat-inactivated HSV-1. Boll. Ocul. Anno 75, n.1, 1996, 1-12.
99	Battista MC, et al. Use of antiherpetic vaccine, derived from herpes simplex virus heat killed, in the prevention of recurrent eye infections from HSV. Boll. Ocul. Anno 75, n.1, 1996, 13-28.
100	Ferrante M, et al. Clinical and immunological evaluation of the efficacy of an antiherpes simplex I vaccine therapy and hypothesis of management of relapsing herpetic keratitis. Boll. Ocul. Anno 75, n.1, 1996, 29-39.
101	Martello C, Anti-herpes vaccine: personal experience on the treatment of keratouveitis by HSV1. Boll. Ocul. Anno 75, n.1, 1996, 41-49.
102	Salvetat M.L. Clinical use of heat-inactivated herpes simplex virus vaccine in the prophylaxis of herpetic dendritic and stromal recurrent keratitis. Boll. Ocul Anno 75 n.1 1996, 51-74
103	Actis G, Further notes on the therapeutic results and immunological response of a heat-inactivated anti-herpes vaccine. Minerva Ophthalmologica. vol. 19, n°2: 48-80; Aprile-Giugno 1977.
104	De Maria A, Use of an antiherpetic vaccine in the HSV1 recurrent infections: preliminary results. Rivista di patologia clinica. Vol XLVIII, n°2; maggio-agosto 1993.
105	Hanissian J. Emerging herpes vaccines. Infect Med 14(3): 205-206, 1997
106	Boursnell ME, Entwisle C, Blakeley D, et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 175(1): 16-25, 1997
107	Cantab Pharmaceuticals DISC HSV erpes vaccine shows safety and immunogenicity in phase I clinical trials. In: 8th International Congress on Infectios Disease, Cantab Pharmaceutical, plc. ,1998
108	Bernstein DI, Ashley RL, Stanberry LR, Myers MG. detection of asymptomatic initial herpes simplex virus (HSV) infections in animals immunized with subunit HSV glycoprotein vaccines. J Clin Microbiol 28(1): 11-15, 1990
109	Stanberry LR, Bernstein DI, Burke RL, Pachl C, Myers MG. Vaccination with recombiannt herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 155(5): 914-920, 1987
110	Berman PW, Vogt PE, Gregory T, Lasky LA, Kern ER. Efficacy of recombiant glycoprotein D subunit vaccines on teh development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs. J Infect Dis 157(5): 897-902, 1988
111	Burke RL, Goldbeck C, ng P, Stanberry L, Ott G, et al. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J Infect Dis 170(5): 1110-1119, 1994
112	McClement WL, Armstrong ME, Keys RD, Liu MA. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci USA 93(21): 11414-11420, 1996
113	Bernstein DI, Tepe ER, Mester JC, Arnold RL, Stanberry LR, Higgins T. Effects of DNA immunization formulated with bupivacaine in murine and guinea pig models of genital herpes simplex virus infection. Vaccine, 17(15-16):1964-1969, 1999
114	Langenberg AG, Burke RL, Adair SF, Sekulovich R, et al. A recombiannt glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity. Ann Intern Med 122(2): 889-898, 1995
115	Ashley R, Mertz GJ, Corey L. Detection of asymptomatic herpes simplex virus infections after vaccination. J Virol 61(2): 264-268, 1987
116	Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, et al. Recombiannt glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomize controlled trials. Chiron HSV vaccine study group. JAMA 282(4): 331-340, 1999
117	Mertz GJ, Ashley R, Burke RL, Benedetti J, et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis 161(4): 653-660, 1990
118	Straus SE, Savarese B, Tigges M, Freifeld AG, Krause PR, et al. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombiannt glycoprotein D vaccine. J Infect Dis 167: 1045-1052, 1993
119	Straus SE, Lawrence C, Burke RL, Savarese B, Barnum G, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343: 1460-1463, 1994
120	Stanberry L R. Control of STDs--the Role of Prophylactic Vaccines against Herpes Simplex Virus. Sex Transm. Inf. 1998;74, 391-394
121	Ghiasi H, Nesburn A B and Wechsler S L. Vaccination with a Cocktail of Seven Recombinatly exjpressed HSV-1 Glycoproteins protects against Ocular HSV-1 Challenge More Efficiently than Vaccination with any Individual Glycoprotein. Vaccine 1996; 14 [2]: 107-112.
122	Bernstein D. Effect of Route of Vaccination with Vaccinia Virus Expressing HSV-2 Glycoprotein D on Protection from Genital HSV-2 Infection. Vaccine 2000; 18: 1351-1358
123	O'Hagen D, Goldbeck C, Ugozzoli M, Ott G and Burke. Intranasal Immunization with Recombinant gD2 Reduces disease Severity and Mortality Following Genital Challenge with Herpes Simplex Virus Type 2 in Guinea Pig Models. Vaccine 1999; 17: 2229-2236.
124	Walker J and Leib D A. Protection from Primary Infection and Establishment of Latency by Vaccination with Herpes Simplex Virus Type I Recombinant Deficient in the Viron Host Shutoff (vhs) Function. Vaccine 1998; 16[1], 1-5.
125	Bernstein D I and Stanbery L R. Herpes Simplex Virus Vaccines. Vaccine 1999; 17: 1681-1689.
126	Rosenthal K S, Mao H, Horne W I, Wright C and Zimmerman D. Immunization with a LEAPS(TM) Heteroconjugate Containing a CTL Epitope and a Peptide from Beta-2-microglobulin Elicits a Protective and DTH Response to Herpes Simplex Virus Type 1. Vaccine 1999; 17: 535-542.